Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) Return on Sales (2016 - 2025)

Vistagen Therapeutics' Return on Sales history spans 13 years, with the latest figure at 62.37% for Q4 2025.

  • For Q4 2025, Return on Sales fell 216.0% year-over-year to 62.37%; the TTM value through Dec 2025 reached 84.87%, down 3321.0%, while the annual FY2025 figure was 105.8%, 7820.0% down from the prior year.
  • Return on Sales for Q4 2025 was 62.37% at Vistagen Therapeutics, up from 75.26% in the prior quarter.
  • Across five years, Return on Sales topped out at 909.0% in Q1 2025 and bottomed at 127.77% in Q2 2024.
  • The 4-year median for Return on Sales is 34.52% (2023), against an average of 18.97%.
  • The largest annual shift saw Return on Sales tumbled -9326bps in 2024 before it soared 90033bps in 2025.
  • A 4-year view of Return on Sales shows it stood at 29.43% in 2021, then surged by 47bps to 15.45% in 2023, then tumbled by -290bps to 60.21% in 2024, then decreased by -4bps to 62.37% in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Return on Sales are 62.37% (Q4 2025), 75.26% (Q3 2025), and 61.86% (Q2 2025).